| Literature DB >> 32120311 |
Vanessa Fiorini Furtado1, Kira Melamud2, Khalid Hassan3, Saurabh Rohatgi4, Karen Buch5.
Abstract
Immune checkpoint inhibitors are monoclonal antibodies directed against cellular pathways on T-cells to treat different types of malignancies. This new therapy can cause immune-related adverse events that can involve almost any organ system. This article will review clinical presentations, molecular mechanisms and imaging manifestations of adverse events caused by checkpoint inhibitors and also illustrate the pseudoprogression tumor response pattern.Entities:
Keywords: Checkpoint inhibitors; Immune-related adverse events; Immunotherapy; Pseudoprogression
Year: 2020 PMID: 32120311 DOI: 10.1016/j.clinimag.2020.02.006
Source DB: PubMed Journal: Clin Imaging ISSN: 0899-7071 Impact factor: 1.605